Background: Cutaneous infections induced by Malassezia ovalis (Pityrosporum ovale) represent a therapeutic problem due to the high rate of recurrence. Objective: We studied feasible strategies to control the growth of M. ovalis, compatible with topical use in cosmetic formulations. Studies were performed on the effects of pH, ionic strength, cinnamic acid and related compounds on mycotic growth. Methods:M. ovalis was cultivated in modified Sabouraud agar. The effects of pH, ionic strength and cinnamic acid and related compounds on mycotic growth were studied by the membrane filter method. Results: In vitro growth of M. ovalis is strongly affected by pH and ionic strength. pH 4.5 induced a growth inhibition of about 95% and 1 M NaCl, at the optimal growth pH, reduced cell growth by over 90%. Cinnamic acid showed an inhibitory effect of 50% at 0.005 g/dl; 30 min incubation with cinnamic acid 0.5 g/dl had a mycocidic effect. Conclusion: These results suggest the use of cosmetic compositions containing cinnamic acid or buffered acidic lotions and shampoos in the treatment of M. ovalis infections of the scalp, eventually in addition or alternative to antimycotic drugs or in maintenance therapy. Cosmetic formulations with high ionic strength or skin irritant derivatives such as cinnamaldehyde cannot be proposed for practical use.

Keywords:
Malassezia ovalis, Dandruff, Ionic strength, pH, Cinnamic acid
1.
Faergemann J: Pityrosporum infections; in Elewski BE (ed): Cutaneous Fungal Infections. Tokio, Igaku-Schoin, 1992, pp 69–83.
2.
Keddi FM: Electron microscopy of Malassezia furfur in tinea versicolor. Sabouraudia 1966;5:134–137.
3.
Back O, Faergemann J, Hornqvist R: Pityrosorum folliculitis: A common disease of the young and middle aged. J Am Acad Dermatol 1985;12:56–61.
4.
Faergemann J: Lipophilic yeasts in skin diseases. Semin Dermatol 1985;4:173–184.
5.
Bergbrant IM, Faergemann J: The role of Malassezia ovalis in seborrheic dermatitis. Semin Dermatol 1990;9:262–268.
6.
Waersted A, Hjorth N: Pityrosporum orbiculare: A pathogenic factor in atopic dermatitis of the face, scalp and neck? Acta Derm Venereol Suppl (Stockh) 1985;114:146–148.
7.
Rosenberg EW, Noah PW: The Koebner phenomenon and the microbial basis of psoriasis. J Am Acad Dermatol 1988;18:151–158.
8.
Yu HJ, Lee SK, Son SJ, Kim YS, Yang HY, Kim JH: Steroid acne vs Pityrosporum folliculitis: The incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol 1998;37:772–777.
9.
Kellett JK, MacDonald RH: Confluent and reticulate papillomatosis. Arch Dermatol 1985;121:587–588.
10.
Porro MN, Passi S, Caprilli F, Nazzaro P, Morpurgo G: Growth requirements and lipid metabolism of Pityrosporum orbiculare. J Invest Dermatol 1976;66:178–182.
11.
Hammer KA, Carson CF, Riley TV: In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob Agents Chemother 2000;44:467–469.
12.
Strippoli V, Piacentini A, D’Auria FD, Simonetti N: Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo. Infection 1997;25:303–306.
13.
Faergemann J, Bratel AT: The in vitro effect of fluconazole on the filamentous form of Malassezia ovalis. Acta Derm Venereol 1996;76:444–446.
14.
Palacin C, Tarrago C, Ortiz JA: In vitro activity of sertaconazole against Malassezia furfur and pachydermatis in different culture media. Methods Find Exp Clin Pharmacol 1998;20:451–455.
15.
Nicholas RO, Berry V, Hunter PA, Kelly JA: The antifungal activity of mupirocin. J Antimicrob Chemother 1999;43:579–582.
16.
Gupte TE, Gaikwad UV, Naik SR: Experimental studies (in vitro) on polyene macrolide antibiotics with special reference to hamycin against Malassezia ovale. Comp Immunol Microbiol Infect Dis 1999;22:93–102.
17.
Leeming JP, Sansom JE, Burton JL: Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997;137:764–767.
18.
Nenoff P, Haustein UF: In vitro susceptibility testing of Malassezia furfur against rilopirox. Skin Pharmacol 1997;10:275–280.
19.
Alves EV, Martins JE, Ribeiro EB, Sotto MN: Pityrosporum folliculitis: Renal transplantation case report. J Dermatol 2000;27:49–51.
20.
Rhie S, Turcios R, Buckley H, Suh B: Clinical features and treatment of Malassezia folliculitis with fluconazole in orthotopic heart transplant recipients. J Heart Lung Transplant 2000;19:215–219.
21.
Savin R, Eisen D, Fradin MS, Lebwohl M: Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol 1999;38:863–865.
22.
Arrese JE, Piérard-Franchimont C, De Doncker P, Heremans A, Cauwenbergh G, Piérard GE: Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutis 1996;58:235–237.
23.
Lesher JL Jr: Oral therapy of common superficial fungal infections of the skin. J Am Acad Dermatol 1999;40:S31–S34.
24.
Florianowicz T: Penicillium expansum growth and production of patulin in the presence of benzoic acid and its derivatives. Acta Microbiol Pol 1998;47:45–53.
25.
Tawata S, Taira S, Kobamoto N, Zhu J, Ishihara M, Toyama S: Synthesis and antifungal activity of cinnamic acid esters. Biosci Biotechnol Biochem 1996;60:909–910.
26.
Faergemann J: Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol 1994;72:74–75.
27.
Gergely P, Nekam K, Lang I, Kalmar L, Gonzalez-Cabello R, Perl A: Ketoconazole in vitro inhibits mitogen-induced blastogenesis, antibody-dependent cellular cytotoxicity, natural killer activity and random migration of human leukocytes. Immunopharmacology 1984;7:167–170.
28.
Johnson EM, Warnock DW, Richardson MD, Douglas CJ: In vitro effect of itraconazole, ketoconazole and amphotericin B on the phagocytic and candidacidal function of human neutrophils. J Antimicrob Chemother 1986;18:83–91.
29.
Vuddhakul V, Mai GT, McCormack JG, Seow WK, Thong YH: Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole. Int J Immunopharmacol 1990;12:639–645.
30.
Vuddhakul V, McCormack JG, Seow WK, Thong YH: Effects of the newer antifungal agents (bifonazole, ICI195, 739 and amorolfin) on in vitro phagocytic, lymphocytic and natural-killer cell responses. Int J Immunopharmacol 1989;11:817–828.
31.
Janssen PA, Van den Bossche H, Van Wauwe JP, Cauwenbergh GF, Degreef HJ: The role of cytochrome P-450 in dermatology. Int J Dermatol 1989;28:493–496.
32.
Baroni A, Ruocco V, De Paolis P, Cicatiello L, Esumi H, Tufano MA: Ketoconazole inhibits lipopolysaccharide-induced activation of the nitric oxide synthase gene in the murine macrophage cell line J774. Arch Dermatol Res 1999;291:54–58.
33.
Johansen JD, Andersen KE, Rastogi SC, Menne T: Threshold responses in cinnamic-aldehyde-sensitive subjects: Results and methodological aspects. Contact Dermatitis 1996;34:165–171.
34.
Pigatto P, Bigardi A, Legori A, Valsecchi R, Picardo M: Cross-reaction in patch testing and photopatch testing with ketoprofen, thiaprophenic acid, and cinnamic aldehyde. Am J Contact Dermatitis 1996;7:220–223.
35.
Rastogi SC, Johansen JD, Frosch P, Menne T, Bruze M, Lepoittevin JP, Dreier B, Andersen KE, White IR: Deodorants on the European market: Quantitative chemical analysis of 21 fragrances. Contact Dermatitis 1998;38:29–35.
36.
Schorr WF: Cinnamic aldehyde allergy. Contact Dermatitis 1975;1:108–111.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.